Perjeta (Pertuzumab) Injection - 420mg Single-Use Vial for Intravenous Infusion

Perjeta; box and bottle
Perjeta; front
Perjeta; side
Perjeta; side
Perjeta; side
Perjeta; top
Perjeta; bottom
Perjeta; bottle
Perjeta; bottle
Perjeta; bottle
Perjeta; bottle
Description (Brief):

(From box) Dilute prior to use; for intravenous infusion only; single-use vial; discard unused portion

Description (Brief)

(From insert)

Description (Brief)

PERJETA is a HER2/neu receptor antagonist indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Date Made: ca 2013Product Expiration Date: 2014-02

Maker: Genentech, Inc.

Location: Currently not on view

Place Made: United States: California, South San Francisco

Subject: Women's Health

Subject:

See more items in: Medicine and Science: Medicine, Health & Medicine, The Antibody Initiative, Antibody Initiative: Monoclonal Antibodies

Exhibition:

Exhibition Location:

Credit Line: Gift of Genentech, Inc.

Data Source: National Museum of American History

Id Number: 2013.0069.09Catalog Number: 2013.0069.09Accession Number: 2013.0069

Object Name: pharmaceuticalbiological

Physical Description: plastic (overall material)glass (overall material)metal (overall material)cardboard (overall material)pertuzumab, 420mg/14 mL (overall ingredient)Measurements: overall: 1 3/4 in x 2 3/4 in x 3 1/8 in; 4.445 cm x 6.985 cm x 7.9375 cmoverall: 3 in x 2 1/8 in x 2 1/8 in; 7.62 cm x 5.3975 cm x 5.3975 cm

Metadata Usage: CC0

Guid: http://n2t.net/ark:/65665/ng49ca746ad-d916-704b-e053-15f76fa0b4fa

Record Id: nmah_1445190

Our collection database is a work in progress. We may update this record based on further research and review. Learn more about our approach to sharing our collection online.

If you would like to know how you can use content on this page, see the Smithsonian's Terms of Use. If you need to request an image for publication or other use, please visit Rights and Reproductions.